Developing therapies to treat hepatitis C infection in post-liver transplant recipients

References

• Holmberg SD, Spradling PR, Moorman AC, et al. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–1861.
   PubMed Web of Science ®Google Scholar
• Wasley A, Grytdal S, Gallagher K. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis – United States, 2006. MMWR Surveill Summ. 2008;57:1–24.
   PubMedGoogle Scholar
• Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 2003;9:331–338.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
   PubMed Web of Science ®Google Scholar
• Viral Hepatitis - Statistics & Survelliance. CDC – Centers for Disease Control and Prevention. [cited 2016 Sep 21]. Available from: http://www.cdc.gov/hepatitis/statistics/incidencearchive.htm
   Google Scholar
• Rein DB, Borton J, Liffmann DK, et al. The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics. Hepatology. 2016;63:1135–1144.
   PubMed Web of Science ®Google Scholar
• Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 1996;61:701–705.
   PubMed Web of Science ®Google Scholar
• Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317–322.
   PubMed Web of Science ®Google Scholar
• Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–687.
   PubMed Web of Science ®Google Scholar
• Feinstone SM, Kapikian AZ, Purcell RH, et al. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292:767–770.
   PubMed Web of Science ®Google Scholar
• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135.
   PubMed Web of Science ®Google Scholar
• Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis interventional therapy group. N Engl J Med. 1989;321:1501–1506.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510.
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591–598.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med. 1998;339:1485–1492.
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–1432.
   PubMed Web of Science ®Google Scholar
• Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc. 2005;37:2207–2208.
   PubMed Web of Science ®Google Scholar
• Dumortier J, Scoazec J-Y, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 2004;40:669–674.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004;77:190–194.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Rogge J, Weaver L, et al. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc. 2003;35:3042–3044.
   PubMed Web of Science ®Google Scholar
• Neff GW, Montalbano M, O’Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation. 2004;78:1303–1307.
   PubMed Web of Science ®Google Scholar
• Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation. 2006;82:43–47.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–298.
   PubMed Web of Science ®Google Scholar
• Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007;46:1009–1017.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis. 2003;37(Suppl 4):S315–S322.
   PubMed Web of Science ®Google Scholar
• Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
   PubMed Web of Science ®Google Scholar
• Vinaixa C, Rubin A, Aguilera V, et al. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol. 2013;26:304–313.
   PubMedGoogle Scholar
• Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–1599.
   PubMed Web of Science ®Google Scholar
• Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142(1132–9):e1.
   Google Scholar
• Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159–1165.
   PubMed Web of Science ®Google Scholar
• Coilly A, Roche T, Antonini T, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation; a first multicentric experience. Hepatology. 2012;56(Suppl):9.
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transplant. 2013;19:690–700.
   PubMed Web of Science ®Google Scholar
• Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:78–86.
   PubMed Web of Science ®Google Scholar
• Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transplant. 2012;18:1464–1470.
   PubMed Web of Science ®Google Scholar
• Werner CR, Egetemeyr DP, Lauer UM, et al. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. Plos One. 2013;8:e80528.
   Google Scholar
• Burton JR Jr., O’Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014;61:508–514.
   PubMed Web of Science ®Google Scholar
• Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.
   Google Scholar
• Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis c after liver transplantation. Hepatology. 2015;61:1485–1494.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Brown K, Burton J, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin for 12 weeks in subjects with recurrent genotype 1 hepatitis C post-orthotopic liver transplant: the galaxy study. J Hepatol. 2016;64(Suppl 2):S540.
   Google Scholar
• Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61:1880–1886.
   PubMed Web of Science ®Google Scholar
• Brown RS Jr., O’Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22:24–33.
   PubMed Web of Science ®Google Scholar
• Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442–2447.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–1505.
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–697.
   PubMed Web of Science ®Google Scholar
• Nguyen NH, Yee BE, Chang C, et al. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol. 2016;3:e000066.
   Google Scholar
• Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. Safety announcement. [cited 2016 Sep 21]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM468755.pdf
   Google Scholar
• Menon R, Badri P, Khatri A, et al. ABT-450/ritonavir +ombitasvir + dasabuvir: drug interactions mediated by transporters. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2014 May 19–21; Washington, DC.
   Google Scholar
• Abbvie Corporation. Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information. 2014 Dec; North Chicago (IL).
   Google Scholar
• Kwo PJ, Mantry PS, Coakley E, et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [abstract O114]. 49th Annual Meeting of the European Association for the Study of the Liver (EASL); 2014 Apr 9–13; London.
   Google Scholar
• Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014;57:5057–5071.
   PubMed Web of Science ®Google Scholar
• Gilead Files for U.S. Approval of ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [cited 2016 Sep]. Available from: http://www.gilead.com/news/press-releases/2014/2/gilead-files-for-us-approval-of-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-genotype-1-hepatitis-c
   Google Scholar
• U.S. Food and Drug Administration approves Gilead’s harvoni® (Ledipasvir/Sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C. [cited 2016 Sep 15]. Available from: http://www.gilead.com/news/press-releases/2014/10/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-oncedaily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c
   Google Scholar
• U.S. FDA approves two supplemental indications for harvoni® in chronic hepatitis C patients with advanced liver disease. [cited 2016 Sep 17]. Available from: http://www.gilead.com/news/press-releases/2016/2/us-fda-approves-two-supplemental-indications-for-harvoni-in-chronic-hepatitis-c-patients-with-advanced-liver-disease
   Google Scholar
• A Special Meeting Review Edition. Advances in the treatment of hepatitis C virus infection from EASL 2015: April 22-26, 2015 * Vienna, Austria. Steven L. Flamm. Gastroenterol Hepatol. 2015;11:1–23.
   Google Scholar
• Dore G, Altice F, Litwin AH, et al. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. Presented at the 2015 Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13–17; San Francisco, CA. Abstract 40.
   Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62:32–36.
   PubMed Web of Science ®Google Scholar
• Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5 or 6 infection. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22–26; Vienna, Abstract P0771.
   Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–1097.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–e327.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55:605–613.
   PubMed Web of Science ®Google Scholar
• Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers [abstract 1869]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2012Nov 9–13; Boston, MA.
   Google Scholar
• Zuckerman E, Ashkenasi E, Kovaleve Y, et al. The real world Israeli experience of treating chronic hepatitis C genotype 1 patients with advanced fibrosis with parataprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large, multi-center cohort. J Hepatol. 2016;64. PS004 (Abstract).
   Google Scholar
• FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. [cited 2016 Sep 21] Available from: http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm
   Google Scholar
• Schwabi P, Mandorfer M, Steiner S, et al. Interferon-free DAA regimens decrease portal pressure and halt histological necroinflammation in HIV/HCV coinfected patients. EASL J Hep. 2016;64:2, Supp S623.
   Google Scholar
• Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004;10:1120–1130.
   PubMed Web of Science ®Google Scholar
• Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–531.
   PubMed Web of Science ®Google Scholar
• Tapper EB, Hughes MS, Buti M, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with child B and C cirrhosis: a cost-effectiveness analysis. Transplantation. 2016.
   PubMedGoogle Scholar
• Njei B, McCarty TR, Fortune BE, et al. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016;44:1090–1101.
   PubMed Web of Science ®Google Scholar
• Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734–740.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–733.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–726.
   PubMed Web of Science ®Google Scholar